{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T04:04:10Z","timestamp":1788581050149,"version":"build-2803163510"},"reference-count":136,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100006510","name":"Duke University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006510","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ahj.2026.107446","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T22:59:48Z","timestamp":1777589988000},"page":"107446","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Secondary prevention strategies for patients with lower extremity peripheral artery disease after successful peripheral vascular intervention"],"prefix":"10.1016","volume":"299","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8158-4786","authenticated-orcid":false,"given":"Pishoy","family":"Gouda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric A.","family":"Secemsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connie N.","family":"Hess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shipra","family":"Arya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Foluso","family":"Fokorede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxana","family":"Mehran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc P.","family":"Bonaca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manesh R.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7288-9596","authenticated-orcid":false,"given":"William Schuyler","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2026.107446_bib0001","doi-asserted-by":"crossref","first-page":"e1020","DOI":"10.1016\/S2214-109X(19)30255-4","article-title":"Global, regional, and national prevalence and risk factors for peripheral artery disease in 2015: an updated systematic review and analysis","volume":"7","author":"Song","year":"2019","journal-title":"Lancet Global Health"},{"key":"10.1016\/j.ahj.2026.107446_bib0002","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1001\/jama.286.11.1317","article-title":"Peripheral arterial disease detection, awareness, and treatment in primary care","volume":"286","author":"Hirsch","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2026.107446_bib0003","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.atherosclerosis.2019.09.012","article-title":"Morbidity and mortality associated with atherosclerotic peripheral artery disease: a systematic review","volume":"293","author":"Agnelli","year":"2020","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ahj.2026.107446_bib0004","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1001\/jamasurg.2014.1007","article-title":"Fifteen-year trends in lower limb amputation, revascularization, and preventive measures among Medicare patients","volume":"150","author":"Goodney","year":"2015","journal-title":"JAMA Surg"},{"key":"10.1016\/j.ahj.2026.107446_bib0005","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1093\/eurheartj\/ehae867","article-title":"Lifetime risk of lower extremity peripheral arterial disease: a Danish nationwide longitudinal study","volume":"46","author":"S\u00f8gaard","year":"2025","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2026.107446_bib0006","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ehj.2003.10.033","article-title":"Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease","volume":"25","author":"Ostergren","year":"2004","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2026.107446_bib0007","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.021801","article-title":"Ankle-brachial index and subsequent risk of severe ischemic leg outcomes: the ARIC study","volume":"10","author":"Paskiewicz","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ahj.2026.107446_bib0008","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1001\/archinte.167.22.2482","article-title":"A prognostic risk index for long-term mortality in patients with peripheral arterial disease","volume":"167","author":"Feringa","year":"2007","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ahj.2026.107446_bib0009","doi-asserted-by":"crossref","unstructured":"Wu A, Coresh J, Selvin E, et al. Lower extremity peripheral artery disease and quality of life among older individuals in the community. J Am Heart Assoc.6:e004519.","DOI":"10.1161\/JAHA.116.004519"},{"key":"10.1016\/j.ahj.2026.107446_bib0010","first-page":"21","article-title":"Rivaroxaban and aspirin in patients with symptomatic lower extremity peripheral artery disease: a subanalysis of the COMPASS randomized clinical trial","volume":"6","author":"Kaplovitch","year":"2021","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.ahj.2026.107446_bib0011","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.jacc.2018.06.041","article-title":"Major adverse limb events and 1-year outcomes after peripheral artery revascularization","volume":"72","author":"Hess Connie","year":"2018","journal-title":"JACC"},{"key":"10.1016\/j.ahj.2026.107446_bib0012","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/archinte.163.8.884","article-title":"Critical issues in peripheral arterial disease detection and management: a call to action","volume":"163","author":"Belch","year":"2003","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ahj.2026.107446_bib0013","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ejvs.2023.08.067","article-title":"Editor's Choice: European Society for Vascular Surgery (ESVS) 2024 clinical practice guidelines on the management of asymptomatic lower limb peripheral arterial disease and intermittent claudication*","volume":"67","author":"Nordanstig","year":"2024","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1016\/j.ahj.2026.107446_bib0014","doi-asserted-by":"crossref","first-page":"e1313","DOI":"10.1161\/CIR.0000000000001251","article-title":"2024 ACC\/AHA\/AACVPR\/APMA\/ABC\/SCAI\/SVM\/SVN\/SVS\/SIR\/VESS Guideline for the management of lower extremity peripheral artery disease: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"149","author":"Gornik","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2026.107446_bib0015","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1016\/j.jacc.2024.02.013","article-title":"2024 ACC\/AHA\/AACVPR\/APMA\/ABC\/SCAI\/SVM\/SVN\/SVS\/SIR\/VESS guideline for the management of lower extremity peripheral artery disease: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"83","author":"Gornik","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2026.107446_bib0016","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1161\/ATVBAHA.120.315828","article-title":"Conventional and novel lipid measures and risk of peripheral artery disease","volume":"41","author":"Kou","year":"2021","journal-title":"Arterioscleros Thrombos Vasc Biol"},{"issue":"16","key":"10.1016\/j.ahj.2026.107446_bib0017","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1001\/jama.2012.13415","article-title":"Associations between conventional cardiovascular risk factors and risk of peripheral artery disease in men","volume":"308","author":"Joosten","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2026.107446_bib0018","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1161\/CIRCULATIONAHA.105.608679","article-title":"Risk factors for progression of peripheral arterial disease in large and small vessels","volume":"113","author":"Aboyans","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2026.107446_bib0019","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1161\/CIRCULATIONAHA.122.063399","article-title":"Association between achieved low-density lipoprotein cholesterol levels and long-term cardiovascular and safety outcomes: an analysis of FOURIER-OLE","volume":"147","author":"Gaba","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2026.107446_bib0020","doi-asserted-by":"crossref","first-page":"4359","DOI":"10.1093\/eurheartj\/ehaf190","article-title":"2025 Focused update of the 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: developed by the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)","volume":"46","author":"Mach","year":"2025","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2026.107446_bib0021","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1161\/CIRCULATIONAHA.117.032235","article-title":"Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER trial (further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk)","volume":"137","author":"Bonaca","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2026.107446_bib0022","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jjcc.2023.10.002","article-title":"The real-world data of lipid-lowering treatment in patients with peripheral artery disease and its association with severity of disease","volume":"84","author":"Komai","year":"2024","journal-title":"J Cardiol"},{"key":"10.1016\/j.ahj.2026.107446_bib0023","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1016\/j.jacc.2021.04.060","article-title":"Effectiveness of blood lipid management in patients with peripheral artery disease","volume":"77","author":"Hess Connie","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2026.107446_bib0024","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1161\/CIRCULATIONAHA.117.032361","article-title":"Association of statin dose with amputation and survival in patients with peripheral artery disease","volume":"137","author":"Arya","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2026.107446_bib0025","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1093\/eurheartj\/ehu080","article-title":"Statin therapy and long-term adverse limb outcomes in patients with peripheral artery disease: insights from the REACH registry","volume":"35","author":"Kumbhani","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2026.107446_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103391","article-title":"Clinician underprescription of and patient nonadherence to clinical practice guideline-recommended medications for peripheral artery disease: a systematic review and meta-analysis","volume":"86","author":"Kirkham","year":"2025","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.ahj.2026.107446_bib0027","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.ejvs.2025.09.015","article-title":"Adherence to antithrombotic and lipid lowering therapy and clinical outcomes in patients with lower extremity peripheral arterial disease: a nationwide nested case\u2013control study","volume":"71","author":"S\u00f8gaard","year":"2026","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1016\/j.ahj.2026.107446_bib0028","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.vph.2014.09.001","article-title":"Statin therapy in lower limb peripheral arterial disease: systematic review and meta-analysis","volume":"63","author":"Antoniou","year":"2014","journal-title":"Vasc Pharmacol"},{"key":"10.1016\/j.ahj.2026.107446_bib0029","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.jvs.2006.12.054","article-title":"Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions","volume":"45","year":"2007","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.ahj.2026.107446_bib0030","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.36014","article-title":"Prescribing of statins after lower extremity revascularization procedures in the US","volume":"4","author":"Singh","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ahj.2026.107446_bib0031","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.018338","article-title":"Long-term effectiveness and safety of initiating Statin therapy after index revascularization in patients with peripheral arterial occlusive disease","volume":"9","author":"Peters","year":"2020","journal-title":"J Am Heart Assoc"},{"issue":"Supplement_2","key":"10.1016\/j.ahj.2026.107446_bib0032","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehad655.2034","article-title":"Reduction in the risk of major adverse limb events with ezetimibe versus placebo in addition to statin therapy: insights from the IMPROVE IT trial","volume":"44","author":"Bonaca","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2026.107446_bib0033","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ahj.2026.107446_bib0034","doi-asserted-by":"crossref","DOI":"10.1161\/circ.144.suppl_1.10627","article-title":"Abstract 10627: benefits of icosapent ethyl in patients with prior peripheral artery disease: REDUCE-IT PAD","volume":"144","author":"Bhatt","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2026.107446_bib0035","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1161\/CIRCULATIONAHA.122.059410","volume":"146","author":"Ridker","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2026.107446_bib0036","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","article-title":"Bempedoic acid and cardiovascular outcomes in statin-intolerant patients","volume":"388","author":"Nissen","year":"2023","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ahj.2026.107446_bib0037","doi-asserted-by":"crossref","DOI":"10.1161\/circ.150.suppl_1.4139186","article-title":"Abstract 4139186: bempedoic acid and limb outcomes in statin-intolerant patients with peripheral artery disease","volume":"150","author":"Bonaca","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2026.107446_bib0038","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1161\/CIRCULATIONAHA.117.032235","article-title":"Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease","volume":"137","author":"Bonaca","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2026.107446_bib0039","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1161\/CIRCULATIONAHA.120.046524","article-title":"Peripheral artery disease and venous thromboembolic events after acute coronary syndrome","volume":"141","author":"Schwartz","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2026.107446_bib0040","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","article-title":"Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk","volume":"139","author":"O\u2019Donoghue","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2026.107446_bib0041","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ahj.2026.107446_bib0042","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1056\/NEJMoa2210645","article-title":"Triglyceride lowering with pemafibrate to reduce cardiovascular risk","volume":"387","author":"Das Pradhan","year":"2022","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ahj.2026.107446_bib0043","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1016\/S0140-6736(09)60698-X","article-title":"Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial","volume":"373","author":"Rajamani","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2026.107446_bib0044","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD009580.pub2","article-title":"Fibrates for secondary prevention of cardiovascular disease and stroke","author":"Wang","year":"2015","journal-title":"Cochr Datab System Rev"},{"key":"10.1016\/j.ahj.2026.107446_bib0045","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/j.jacc.2021.07.022","article-title":"Side effect patterns in a crossover trial of statin, placebo, and no treatment","volume":"78","author":"Howard James","year":"2021","journal-title":"JACC"},{"key":"10.1016\/j.ahj.2026.107446_bib0046","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1024\/0301-1526\/a001223","article-title":"The medicine doesn\u2019t interest me at all.\u201d beliefs, health behaviors, and medication adherence in peripheral arterial disease","volume":"54","author":"H\u00f8jen","year":"2025","journal-title":"Vasa"},{"key":"10.1016\/j.ahj.2026.107446_bib0047","doi-asserted-by":"crossref","first-page":"498","DOI":"10.3390\/jcm11030498","article-title":"Distribution of mobile health applications amongst patients with symptomatic peripheral arterial disease in Germany: a cross-sectional survey study","volume":"11","author":"Alushi","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.ahj.2026.107446_bib0048","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1001\/jama.2009.623","article-title":"Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials","volume":"301","author":"Berger","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2026.107446_bib0049","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1001\/jama.2010.221","article-title":"Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial","volume":"303","author":"Fowkes","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2026.107446_bib0050","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD000535.pub2","article-title":"Antiplatelet agents for preventing thrombosis after peripheral arterial bypass surgery","author":"Brown","year":"2008","journal-title":"Cochr Datab System Rev"},{"key":"10.1016\/j.ahj.2026.107446_bib0051","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","article-title":"A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)","volume":"348","year":"1996","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ahj.2026.107446_bib0052","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/eurheartj\/ehn534","article-title":"Patients with peripheral arterial disease in the CHARISMA trial","volume":"30","author":"Cacoub","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2026.107446_bib0053","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1611688","article-title":"Ticagrelor versus clopidogrel in symptomatic peripheral artery disease","volume":"376","author":"Hiatt","year":"2017","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ahj.2026.107446_bib0054","doi-asserted-by":"crossref","first-page":"e771","DOI":"10.1161\/CIR.0000000000001328","article-title":"2025 ACC\/AHA\/ACEP\/NAEMSP\/SCAI guideline for the management of patients with acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"151","author":"Rao","year":"2025","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2026.107446_bib0055","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ahj.2024.03.002","article-title":"Ticagrelor with or without aspirin following percutaneous coronary intervention in high-risk patients with concomitant peripheral artery disease: a subgroup analysis of the TWILIGHT randomized clinical trial","volume":"272","author":"Krucoff","year":"2024","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2026.107446_bib0056","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1177\/1358863X19892690","article-title":"Effect of vorapaxar on cardiovascular and limb outcomes in patients with peripheral artery disease with and without coronary artery disease: analysis from the TRA 2 P-TIMI 50 trial","volume":"25","author":"Qamar","year":"2020","journal-title":"Vasc Med"},{"key":"10.1016\/j.ahj.2026.107446_bib0057","first-page":"e686","article-title":"2016 AHA\/ACC guideline on the management of patients with lower extremity peripheral artery disease: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on clinical Practice guidelines","volume":"135","author":"Gerhard-Herman","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2026.107446_bib0058","doi-asserted-by":"crossref","first-page":"7113","DOI":"10.3390\/ijms22137113","article-title":"Antithrombotic therapy in patients with peripheral artery disease: a focused review on oral anticoagulation","volume":"22","author":"Rivera-Caravaca","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ahj.2026.107446_bib0059","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa065959","article-title":"Oral anticoagulant and antiplatelet therapy and peripheral arterial disease","volume":"357","year":"2007","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ahj.2026.107446_bib0060","first-page":"1","article-title":"The effects of oral anticoagulants in patients with peripheral arterial disease: rationale, design, and baseline characteristics of the Warfarin and Antiplatelet Vascular Evaluation (WAVE) trial, including a meta-analysis of trials","volume":"151","year":"2006","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2026.107446_bib0061","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0140-6736(17)32409-1","article-title":"Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial","volume":"391","author":"Anand","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2026.107446_bib0062","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa2000052","article-title":"Rivaroxaban in peripheral artery disease after revascularization","volume":"382","author":"Bonaca","year":"2020","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ahj.2026.107446_bib0063","first-page":"21","article-title":"Rivaroxaban and Aspirin in patients with symptomatic lower extremity peripheral artery disease: a subanalysis of the COMPASS randomized clinical trial","volume":"6","author":"Kaplovitch","year":"2021","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.ahj.2026.107446_bib0064","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1161\/CIRCULATIONAHA.120.046048","article-title":"The COMPASS trial","volume":"142","author":"Steffel","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2026.107446_bib0065","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1001\/jama.2019.8145","article-title":"Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: the STOPDAPT-2 randomized clinical trial","volume":"321","author":"Watanabe","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2026.107446_bib0066","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1093\/eurheartj\/ehaf718","article-title":"Aspirin or P2Y12 inhibitor monotherapy in atherosclerotic cardiovascular disease?","volume":"47","author":"Galli","year":"2026","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2026.107446_bib0067","doi-asserted-by":"crossref","DOI":"10.1016\/j.jvs.2023.11.005","article-title":"Efficiency and safety of dual pathway inhibition for the prevention of femoropopliteal artery restenosis in repeated endovascular interventions","volume":"79","author":"Yu","year":"2024","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.ahj.2026.107446_bib0068","article-title":"Antithrombotic therapy following lower extremity endovascular revascularization: the results of a survey of vascular specialists","volume":"2","author":"Jarosinski","year":"2024","journal-title":"JVS-Vasc Insights"},{"key":"10.1016\/j.ahj.2026.107446_bib0069","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1001\/archinte.160.19.2934","article-title":"Determinants of peripheral arterial disease in the elderly: the Rotterdam study","volume":"160","author":"Meijer","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ahj.2026.107446_bib0070","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1161\/CIRCULATIONAHA.118.033348","article-title":"Association of blood pressure measurements with peripheral artery disease events: reanalysis of the ALLHAT data","volume":"138","author":"Itoga","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2026.107446_bib0071","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1161\/HYPERTENSIONAHA.124.22832","article-title":"Cardiovascular outcomes in hypertension-treated patients with peripheral artery disease: the VALUE trial","volume":"81","author":"Vrsalovic","year":"2024","journal-title":"Hypertension"},{"key":"10.1016\/j.ahj.2026.107446_bib0072","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/j.jacc.2017.11.006","volume":"71","author":"Whelton","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2026.107446_bib0073","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.008644","article-title":"Associations of obesity with incident hospitalization related to peripheral artery disease and critical limb ischemia in the ARIC study","volume":"7","author":"Hicks","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ahj.2026.107446_bib0074","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1111\/dom.14700","article-title":"Cardiovascular efficacy of liraglutide and semaglutide in individuals with diabetes and peripheral artery disease","volume":"24","author":"Verma","year":"2022","journal-title":"Diab Obes Metab"},{"key":"10.1016\/j.ahj.2026.107446_bib0075","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.031182","article-title":"Study design, rationale, and methodology for promote weight loss in patients with peripheral artery disease who also have obesity: the PROVE trial","volume":"12","author":"Whipple","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ahj.2026.107446_bib0076","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/S0140-6736(25)00509-4","article-title":"Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial","volume":"405","author":"Bonaca","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2026.107446_bib0077","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.2337\/dc13-2303","article-title":"Risk factors for incident peripheral arterial disease in type 2 diabetes: results from the Bypass Angioplasty Revascularization Investigation in type 2 Diabetes (BARI 2D) Trial","volume":"37","author":"Althouse","year":"2014","journal-title":"Diab Care"},{"key":"10.1016\/j.ahj.2026.107446_bib0078","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.2337\/diacare.24.8.1433","article-title":"Peripheral arterial disease in diabetic and nondiabetic patients: a comparison of severity and outcome","volume":"24","author":"Jude","year":"2001","journal-title":"Diab Care"},{"key":"10.1016\/j.ahj.2026.107446_bib0079","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ahj.2026.107446_bib0080","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1159\/000520903","article-title":"Effects of sodium-glucose cotransporter 2 on amputation events: a systematic review and meta-analysis of randomized-controlled trials","volume":"107","author":"See","year":"2022","journal-title":"Pharmacology"},{"key":"10.1016\/j.ahj.2026.107446_bib0081","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1111\/dom.14700","article-title":"Cardiovascular efficacy of liraglutide and semaglutide in individuals with diabetes and peripheral artery disease","volume":"24","author":"Verma","year":"2022","journal-title":"Diab Obes Metabol"},{"key":"10.1016\/j.ahj.2026.107446_bib0082","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ahj.2026.107446_bib0083","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ahj.2026.107446_bib0084","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.2337\/dc18-1094","article-title":"The impact of liraglutide on diabetes-related foot ulceration and associated complications in patients with type 2 diabetes at high risk for cardiovascular events: results from the LEADER trial","volume":"41","author":"Dhatariya","year":"2018","journal-title":"Diab Care"},{"key":"10.1016\/j.ahj.2026.107446_bib0085","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1681\/ASN.2005111204","article-title":"Kidney function and risk of peripheral arterial disease: results from the atherosclerosis risk in Communities (ARIC) study","volume":"18","author":"Wattanakit","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ahj.2026.107446_bib0086","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1053\/j.ackd.2014.07.005","article-title":"Peripheral artery disease and chronic kidney disease: clinical synergy to improve outcomes","volume":"21","author":"Garimella","year":"2014","journal-title":"Adv Chron Kidney Dis"},{"key":"10.1016\/j.ahj.2026.107446_bib0087","doi-asserted-by":"crossref","first-page":"216","DOI":"10.2215\/CJN.05600515","article-title":"CKD and acute and long-term outcome of patients with peripheral artery disease and critical limb ischemia","volume":"11","author":"L\u00fcders","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ahj.2026.107446_bib0088","doi-asserted-by":"crossref","first-page":"3749","DOI":"10.2147\/IJGM.S322417","article-title":"The impact of chronic kidney disease on peripheral artery disease and peripheral revascularization","volume":"14","author":"Serra","year":"2021","journal-title":"Int J Gen Med"},{"key":"10.1016\/j.ahj.2026.107446_bib0089","doi-asserted-by":"crossref","first-page":"827","DOI":"10.4239\/wjd.v12.i6.827","article-title":"Diabetes and peripheral artery disease: a review","volume":"12","author":"Soyoye","year":"2021","journal-title":"World J Diab"},{"key":"10.1016\/j.ahj.2026.107446_bib0090","article-title":"Cilostazol for intermittent claudication","volume":"2014","author":"Bedenis","year":"2014","journal-title":"Cochr Datab System Rev"},{"key":"10.1016\/j.ahj.2026.107446_bib0091","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1177\/1526602818771358","article-title":"Sustained effectiveness of cilostazol after endovascular treatment of femoropopliteal lesions: midterm follow-up from the sufficient treatment of peripheral intervention by cilostazol (STOP-IC) study","volume":"25","author":"Soga","year":"2018","journal-title":"J Endovasc Ther"},{"key":"10.1016\/j.ahj.2026.107446_bib0092","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.jvs.2016.10.098","article-title":"Drug-eluting stenting for femoropopliteal lesions, followed by cilostazol treatment, reduces stent restenosis in patients with symptomatic peripheral artery disease","volume":"65","author":"Zen","year":"2017","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.ahj.2026.107446_bib0093","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.ejvs.2015.10.022","article-title":"The risk of disease progression in peripheral arterial disease is higher than expected: a meta-analysis of mortality and disease progression in peripheral arterial disease","volume":"51","author":"Sigvant","year":"2016","journal-title":"Eur J Vasc Endovasc Surg"},{"issue":"18","key":"10.1016\/j.ahj.2026.107446_bib0094","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1177\/2047487316671181","article-title":"The prognostic effect of cardiac rehabilitation in the era of acute revascularisation and statin therapy: a systematic review and meta-analysis of randomized and non-randomized studies: the Cardiac Rehabilitation Outcome Study (CROS)","volume":"23","author":"Rauch","year":"2020","journal-title":"Eur J Prevent Cardiol"},{"key":"10.1016\/j.ahj.2026.107446_bib0095","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.hlc.2021.04.009","article-title":"Why are we forgetting patients with peripheral arterial disease?","volume":"30","author":"Barraclough","year":"2021","journal-title":"Heart Lung Circul"},{"key":"10.1016\/j.ahj.2026.107446_bib0096","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s40279-014-0261-z","article-title":"Exercise training for management of peripheral arterial disease: a systematic review and meta-analysis","volume":"45","author":"Parmenter","year":"2015","journal-title":"Sports Med"},{"key":"10.1016\/j.ahj.2026.107446_bib0097","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jacbts.2020.08.012","article-title":"Exercise training and revascularization in the management of symptomatic peripheral artery disease","volume":"6","author":"Biswas","year":"2021","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.ahj.2026.107446_bib0098","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1001\/jama.2015.14851","article-title":"Endovascular revascularization and supervised exercise for peripheral artery disease and intermittent claudication: a randomized clinical trial","volume":"314","author":"Fakhry","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2026.107446_bib0099","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1001\/jama.2013.280618","article-title":"Association of Mediterranean diet with peripheral artery disease: the PREDIMED randomized trial","volume":"311","author":"Ruiz-Canela","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2026.107446_bib0100","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/j.jvs.2014.08.064","article-title":"Smoking cessation is associated with decreased mortality and improved amputation-free survival among patients with symptomatic peripheral artery disease","volume":"60","author":"Armstrong","year":"2014","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.ahj.2026.107446_bib0101","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1001\/jamacardio.2021.3979","article-title":"Association of smoking with postprocedural complications following open and endovascular interventions for intermittent claudication","volume":"7","author":"Reitz","year":"2022","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.ahj.2026.107446_bib0102","doi-asserted-by":"crossref","DOI":"10.1016\/j.jvs.2021.07.248","article-title":"A meta-analysis of randomized controlled trials evaluating the efficacy of smoking cessation interventions in people with peripheral artery disease","volume":"75","author":"Thanigaimani","year":"2022","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.ahj.2026.107446_bib0103","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.010076","article-title":"Underutilization of evidence-based smoking cessation support strategies despite high smoking addiction burden in peripheral artery disease specialty care: insights from the International PORTRAIT Registry","volume":"7","author":"Patel","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ahj.2026.107446_bib0104","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1016\/j.jacc.2010.07.031","article-title":"Effectiveness of a smoking cessation program for peripheral artery disease patients","volume":"56","author":"Hennrikus","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2026.107446_bib0105","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1161\/CIRCULATIONAHA.109.865600","article-title":"Mortality and vascular morbidity in older adults with asymptomatic versus symptomatic peripheral artery disease","volume":"120","author":"Diehm","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2026.107446_bib0106","doi-asserted-by":"crossref","unstructured":"Hiatt William R, Fowkes FGR, Heizer G, et al. Ticagrelor versus clopidogrel in symptomatic peripheral artery disease. New Engl J Med.376:32\u201340.","DOI":"10.1056\/NEJMoa1611688"},{"key":"10.1016\/j.ahj.2026.107446_bib0107","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa2000052","article-title":"Rivaroxaban in peripheral artery disease after revascularization","volume":"382","author":"Bonaca","year":"2020","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ahj.2026.107446_bib0108","article-title":"Effects of additional exercise therapy after a successful vascular intervention for patients with symptomatic peripheral arterial disease","volume":"2021","author":"Cucato","year":"2021","journal-title":"Cochr Datab Systemat Rev"},{"key":"10.1016\/j.ahj.2026.107446_bib0109","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1161\/CIRCULATIONAHA.120.047994","article-title":"Temporal changes in secondary prevention and cardiovascular outcomes after revascularization for peripheral arterial disease in Denmark","volume":"143","author":"S\u00f8gaard","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2026.107446_bib0110","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1177\/1358863X221083701","article-title":"Frailty and outcomes following revascularization of lower-extremity peripheral artery disease: insights from the Vascular Quality Initiative (VQI)","volume":"27","author":"Al-Damluji","year":"2022","journal-title":"Vasc Med"},{"key":"10.1016\/j.ahj.2026.107446_bib0111","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.amjcard.2023.05.053","article-title":"Representativeness of peripheral artery disease randomized clinical trials supporting current guidelines","volume":"201","author":"Castro-Dominguez","year":"2023","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2026.107446_bib0112","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2024.117486","article-title":"Applicability and impact of the COMPASS trial in a Canadian population of patients with atherosclerotic disease","volume":"393","author":"Welsh","year":"2024","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ahj.2026.107446_bib0113","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ejvs.2021.10.026","article-title":"Revascularisation for symptomatic peripheral artery disease: external applicability of the VOYAGER PAD trial","volume":"63","author":"S\u00f8gaard","year":"2022","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1016\/j.ahj.2026.107446_bib0114","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.ejvs.2021.05.028","article-title":"Editor's Choice - external applicability of the COMPASS and VOYAGER-PAD trials on patients with symptomatic lower extremity artery disease in France: the COPART Registry","volume":"62","author":"Lap\u00e9bie","year":"2021","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1016\/j.ahj.2026.107446_bib0115","doi-asserted-by":"crossref","first-page":"e700","DOI":"10.1161\/CIR.0000000000000727","article-title":"Implementation of supervised exercise therapy for patients with symptomatic peripheral artery disease: a science advisory from the American Heart Association","volume":"140","author":"Treat-Jacobson","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2026.107446_bib0116","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1177\/1358863X211073622","article-title":"Implementation of supervised exercise therapy in a veteran population with symptomatic claudication","volume":"27","author":"Elissa Altin","year":"2022","journal-title":"Vasc Med"},{"key":"10.1016\/j.ahj.2026.107446_bib0117","article-title":"Impact of interdisciplinary system-wide limb salvage advisory council on lower extremity major amputation","volume":"15","author":"Shishehbor","year":"2022","journal-title":"Circul Cardiovasc Interv"},{"key":"10.1016\/j.ahj.2026.107446_bib0118","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.011184","article-title":"Clinical decision support for peripheral artery disease: answering the call","volume":"7","author":"Monteleone","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ahj.2026.107446_bib0119","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1161\/CIRCRESAHA.121.318224","article-title":"Leveraging machine learning and artificial intelligence to improve peripheral artery disease detection, treatment, and outcomes","volume":"128","author":"Flores","year":"2021","journal-title":"Circul Res"},{"key":"10.1016\/j.ahj.2026.107446_bib0120","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1093\/fampra\/cmad048","article-title":"Peripheral artery disease (PAD) in primary care-educational experiences for PAD primary care in England-a mixed-method study","volume":"40","author":"Bridgwood","year":"2023","journal-title":"Fam Pract"},{"key":"10.1016\/j.ahj.2026.107446_bib0121","article-title":"Multidisciplinary clinician perspectives on peripheral artery disease (PAD) education and a PAD video education tool","volume":"3","author":"Reilly","year":"2025","journal-title":"JVS Vasc Insights"},{"key":"10.1016\/j.ahj.2026.107446_bib0122","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1177\/1358863X251315071","article-title":"Multicomponent interventions designed to support adherence to guideline-recommended therapy in patients with peripheral artery disease: a scoping review","volume":"30","author":"Lampridou","year":"2025","journal-title":"Vasc Med"},{"key":"10.1016\/j.ahj.2026.107446_bib0123","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1001\/jamasurg.2016.0415","article-title":"Efficacy of a guideline-recommended risk-reduction program to improve cardiovascular and limb outcomes in patients with peripheral arterial disease","volume":"151","author":"Hussain","year":"2016","journal-title":"JAMA Surg"},{"key":"10.1016\/j.ahj.2026.107446_bib0124","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s13063-021-05087-x","article-title":"The effect of lifestyle and risk factor modification on occlusive peripheral arterial disease outcomes: standard healthcare vs structured programme: for a randomised controlled trial protocol","volume":"22","author":"Elfghi","year":"2021","journal-title":"Trials"},{"key":"10.1016\/j.ahj.2026.107446_bib0125","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12912-020-00437-7","article-title":"Joelsson-Alm E. Follow-up after surgical treatment for intermittent claudication (FASTIC): a study protocol for a multicentre randomised controlled clinical trial","volume":"19","author":"Haile","year":"2020","journal-title":"BMC Nurs"},{"key":"10.1016\/j.ahj.2026.107446_bib0126","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1161\/CIRCULATIONAHA.109.918417","article-title":"Inflammation in peripheral artery disease","volume":"122","author":"Brevetti","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2026.107446_bib0127","first-page":"588","article-title":"Inflammation as a mechanism and therapeutic target in peripheral artery disease","volume":"38","author":"Chan","year":"2022","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.ahj.2026.107446_bib0128","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.atherosclerosis.2015.01.021","article-title":"Systemic inflammation is higher in peripheral artery disease than in stable coronary artery disease","volume":"239","author":"Rein","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ahj.2026.107446_bib0129","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.avsg.2021.12.011","article-title":"Higher systemic immune-inflammation index is associated with Higher likelihood of peripheral arterial disease","volume":"84","author":"Zhang","year":"2022","journal-title":"Ann Vasc Surg"},{"key":"10.1016\/j.ahj.2026.107446_bib0130","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ijcard.2011.03.030","article-title":"Markers of inflammation in relation to long-term cardiovascular mortality in patients with lower-extremity peripheral arterial disease","volume":"160","author":"Urbonaviciene","year":"2012","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ahj.2026.107446_bib0131","doi-asserted-by":"crossref","first-page":"815","DOI":"10.3390\/jcm14030815","article-title":"Role of C-reactive protein as a predictor of early revascularization and mortality in advanced peripheral arterial disease","volume":"14","author":"Di Stolfo","year":"2025","journal-title":"J Clin Med"},{"key":"10.1016\/j.ahj.2026.107446_bib0132","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1056\/NEJMc2034992","article-title":"Colchicine in patients with chronic coronary disease","volume":"384","author":"Kaiser","year":"2021","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ahj.2026.107446_bib0133","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and safety of low-dose colchicine after myocardial infarction","volume":"381","author":"Tardif","year":"2019","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ahj.2026.107446_bib0134","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1016\/j.jacc.2023.10.009","article-title":"Lipoprotein(a) and risks of peripheral artery disease, abdominal aortic aneurysm, and major adverse limb events","volume":"82","author":"Thomas","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2026.107446_bib0135","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1056\/NEJMoa2211023","article-title":"Small interfering RNA to reduce lipoprotein(a) in cardiovascular disease","volume":"387","author":"O\u2019Donoghue Michelle","year":"2022","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ahj.2026.107446_bib0136","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ahj.2025.03.019","article-title":"Design and rationale of Lp(a)HORIZON trial: assessing the effect of Lipoprotein(a) lowering with Pelacarsen on major cardiovascular events in patients with CVD and elevated Lp(a)","volume":"287","author":"Cho","year":"2025","journal-title":"Am Heart J"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870326001080?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870326001080?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T19:51:58Z","timestamp":1780775518000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870326001080"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":136,"alternative-id":["S0002870326001080"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2026.107446","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Secondary prevention strategies for patients with lower extremity peripheral artery disease after successful peripheral vascular intervention","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2026.107446","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107446"}}